The Filing Desk

BioCryst Pharmaceuticals

BCRX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

BCRX · Last close · November 13, 2026
$7.61
Value BioCryst Pharmaceuticals yourself

BioCryst Pharmaceuticals' revenue rose 94.1% to $875 million in fiscal 2025. Its operating margin was 39.0%, up from −0.6% a year earlier. Free cash flow was $345 million. The diluted share count rose 5.8%.

BIOCRYST PHARMACEUTICALS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001628280-26-012240 Updated
Revenue
$875M
94.1%
Operating margin
39.0%
39.5 pts
Net income
$264M
 
Free cash flow
$345M
 
Return on equity
—
 
Market cap
$2.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What BioCryst Pharmaceuticals does

BioCryst develops and sells medicines for hereditary angioedema, or HAE, and other rare diseases. HAE is an inherited condition that causes sudden swelling attacks. Its main product, ORLADEYO (berotralstat), is a once-daily capsule that prevents HAE attacks. The company says it discovered and developed it internally. It is approved in the United States and several other markets, and a pellet form for children aged 2 to under 12 is approved in the United States.

BioCryst earns revenue from selling ORLADEYO and also sells RAPIVAB, an intravenous flu treatment. It has a partnership with Torii. Its pipeline includes navenibart, an injectable antibody for HAE that it gained by merging with Astria Therapeutics, and early-stage candidates for Netherton syndrome, diabetic macular edema and atopic dermatitis.

The company says it wants to use its sales infrastructure to commercialize more rare disease medicines, whether it finds them itself or gets them through business deals.

Its biggest risks, as it describes them

  • It may not reach sustained profitability.
  • It may need to raise more money and could have trouble doing so.
  • The Astria merger may be harder, costlier or slower to combine than expected, and may not bring the hoped-for benefits.
  • Its drug candidates may not win or keep regulatory approval.
  • Generic or biosimilar competition could cut into the sales of its medicines.
From BioCryst Pharmaceuticals's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments508424389321275
Debt incl. finance leases2982343083193
Net debt (negative means net cash)−210−190−81−2−272
Net debt to EBITDA————−0.8x
Debt to equity—————
Interest coverage−3.0x−1.5x−1.0x−0.0x4.3x
Current ratio5.5x4.9x3.3x2.6x2.1x
Quick ratio5.3x4.6x3.1x2.6x2.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project BioCryst Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What BioCryst Pharmaceuticals says to expect

  • Full year 2026: revenueThe company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million and increased its full year 2026 total revenue outlook, including revenue from RAPIVAB ® (peramivir injection) and the licensing of navenibart European rights, to $715 million to $730 million.
  • Full year 2026: non-GAAP operating expensesThe company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $415 million to $425 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought BioCryst Pharmaceuticals shares on the open market, and 3 insiders sold $4.1 million, $3.5 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
May 18, 2026Amy E McKeeDirectorSold11,180$8.97$100,285Form 4
May 13, 2026Alane P BarnesChief Legal OfficerSold plan62,500$9.54$596,250Form 4
Mar 20, 2026Theresa HeggieDirectorSold49,933$10.11$504,823Form 4
Mar 16, 2026Alane P BarnesChief Legal OfficerSold plan150,000$9.15$1.4 millionForm 4
Dec 22, 2025Alane P BarnesChief Legal OfficerSold plan21,773$7.65$166,563Form 4
Dec 15, 2025Alane P BarnesChief Legal OfficerSold plan21,210$7.65$162,256Form 4
Dec 3, 2025Alane P BarnesChief Legal OfficerSold plan19,770$7.65$151,240Form 4
Dec 2, 2025Alane P BarnesChief Legal OfficerSold plan50,906$7.21$367,032Form 4
Dec 1, 2025Alane P BarnesChief Legal OfficerSold plan91,004$7.10$646,128Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 93 of 97 of 9
Rule of 40−7.0%24.2%133.5%
Altman Z''−8.05−8.82−2.63
Accruals ratio−24.6%−7.3%−16.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailPass
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rosePassFailPass
Revenue rose relative to assetsPassPassPass
F-score4 of 93 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put BioCryst Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
BioCryst PharmaceuticalsFY2594.1%39.0%39.4%—−0.8x7
Harmony BiosciencesFY2521.5%24.0%40.1%48.9%—5Compare
RepligenFY2516.4%7.5%12.7%2.4%−1.7x—Compare
NovavaxFY2564.7%40.3%−22.3%—−1.0x5Compare
TG TherapeuticsFY2587.3%20.0%−4.0%29.0%0.4x4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2625214918157271331451875
Revenue growth−45.4%−4.4%−18.0%136.4%−63.5%782.4%72.3%22.4%36.0%94.1%
Gross profit2424—4516150264327438856
Research and development616785107123209253217175166
Operating income−49−57−94−100−175−178−148−104−2341
Net income−55−66−101−109−183−184−247−226−89264
Diluted EPS (US$)−0.75−0.78−0.98−940.00−1.09−1.03−1.33−1.18−0.431.21
Diluted shares (millions)7484103116167179186192207219
Cash flow
Cash from operations−53−41−93−90−135−142−162−95−52347
Capital expenditure5000021212
Free cash flow−59−41−93−90−136−145−163−97−53345
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation813918153545566585
Balance sheet at fiscal year end
Cash and short-term investments55114104136300508424389321275
Debt incl. finance leases232333551282982343083193
Total assets90178147175335588550517490514
Total liabilities889498137354695845972966633
Shareholders' equity2844938−19−107−295−456−476−119
Margins and ratios
Gross margin91.3%95.5%—92.4%91.3%95.4%97.6%98.7%97.3%97.8%
Operating margin−184.4%−227.9%−456.2%−203.7%−981.1%−113.1%−54.8%−31.3%−0.6%39.0%
Net margin−209.2%−261.2%−490.2%−223.0%−1,026.3%−117.1%−91.2%−68.4%−19.7%30.2%
Free cash flow margin−222.8%−164.7%−450.0%−184.1%−761.4%−92.0%−60.3%−29.4%−11.8%39.4%
Rule of 40 (growth + FCF margin)−268.2%−169.1%−468.0%−47.7%−824.9%690.4%12.1%−7.0%24.2%133.5%
Return on capital——————————
Return on equity−223.7%−154.2%−152.3%−248.9%——————
Return on assets−52.0%−49.1%−62.3%−67.6%−71.7%−39.9%−43.4%−42.5%−17.6%52.5%
Net debt to EBITDA—————————−0.8x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: BioCryst Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with BioCryst Pharmaceuticals.